Just a thought (been a while), but all we have is the suggested retail price or MSRP to go by. Totan could theoretically sell the units on a case by case basis for considerably less to fit the prospective client/hospitals ROI needs.
To your point, if its much more advanced than traditional laproscopy, and the price per procedure is even more in line, then thats a solid business case.
Then again, financing as well as us investors have to reevaluate what the market truly is based on a reduced revenue stream...